Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Catheter-Related Infections | 2 | 2017 | 43 | 0.680 |
Why?
|
| Hematinics | 5 | 2018 | 52 | 0.680 |
Why?
|
| Catheterization, Central Venous | 2 | 2017 | 89 | 0.660 |
Why?
|
| Anti-Infective Agents | 2 | 2017 | 166 | 0.620 |
Why?
|
| Neoplasms | 7 | 2019 | 1667 | 0.500 |
Why?
|
| Neutropenia | 4 | 2019 | 72 | 0.480 |
Why?
|
| Sepsis | 1 | 2017 | 233 | 0.470 |
Why?
|
| Education, Pharmacy | 2 | 2012 | 102 | 0.400 |
Why?
|
| Antineoplastic Agents | 6 | 2019 | 1070 | 0.380 |
Why?
|
| Education, Distance | 1 | 2009 | 34 | 0.340 |
Why?
|
| Problem-Based Learning | 1 | 2009 | 72 | 0.330 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2018 | 161 | 0.320 |
Why?
|
| Students, Pharmacy | 1 | 2009 | 79 | 0.320 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2013 | 74 | 0.320 |
Why?
|
| Erythropoietin | 5 | 2017 | 96 | 0.300 |
Why?
|
| United States Food and Drug Administration | 5 | 2019 | 131 | 0.300 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2019 | 44 | 0.300 |
Why?
|
| Databases, Factual | 1 | 2009 | 622 | 0.280 |
Why?
|
| Red-Cell Aplasia, Pure | 2 | 2018 | 13 | 0.270 |
Why?
|
| Drug Costs | 2 | 2019 | 87 | 0.260 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2013 | 468 | 0.260 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 2 | 2016 | 18 | 0.250 |
Why?
|
| Anaphylaxis | 2 | 2018 | 43 | 0.250 |
Why?
|
| Anemia | 2 | 2017 | 104 | 0.240 |
Why?
|
| Drug Labeling | 4 | 2017 | 32 | 0.230 |
Why?
|
| Filgrastim | 3 | 2019 | 22 | 0.220 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2014 | 148 | 0.220 |
Why?
|
| Drug Industry | 2 | 2019 | 54 | 0.180 |
Why?
|
| Drug Utilization | 2 | 2017 | 119 | 0.170 |
Why?
|
| Virus Activation | 1 | 2019 | 15 | 0.170 |
Why?
|
| Hepatitis B, Chronic | 1 | 2019 | 19 | 0.170 |
Why?
|
| Pyrazoles | 2 | 2019 | 190 | 0.160 |
Why?
|
| Pyrimidines | 2 | 2019 | 178 | 0.160 |
Why?
|
| Root Cause Analysis | 1 | 2018 | 2 | 0.160 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2019 | 25 | 0.160 |
Why?
|
| Cost Savings | 1 | 2019 | 110 | 0.160 |
Why?
|
| Humans | 26 | 2019 | 68618 | 0.150 |
Why?
|
| Natalizumab | 1 | 2017 | 6 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2019 | 331 | 0.150 |
Why?
|
| Antiviral Agents | 1 | 2019 | 211 | 0.150 |
Why?
|
| Hemorrhage | 1 | 2019 | 328 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 1 | 2017 | 62 | 0.140 |
Why?
|
| Drugs, Generic | 1 | 2016 | 17 | 0.140 |
Why?
|
| Immunologic Factors | 1 | 2017 | 87 | 0.140 |
Why?
|
| Multiple Sclerosis | 1 | 2017 | 132 | 0.130 |
Why?
|
| Medicaid | 1 | 2017 | 302 | 0.120 |
Why?
|
| Drugs, Investigational | 1 | 2014 | 18 | 0.120 |
Why?
|
| Peptides | 2 | 2018 | 455 | 0.120 |
Why?
|
| Immunoconjugates | 1 | 2014 | 26 | 0.120 |
Why?
|
| Melanoma | 1 | 2017 | 335 | 0.110 |
Why?
|
| Lymphoma | 1 | 2013 | 116 | 0.110 |
Why?
|
| Heparin | 1 | 2013 | 205 | 0.110 |
Why?
|
| Fever | 1 | 2013 | 96 | 0.110 |
Why?
|
| Epoetin Alfa | 3 | 2018 | 23 | 0.110 |
Why?
|
| Reye Syndrome | 1 | 2012 | 11 | 0.100 |
Why?
|
| Primary Prevention | 1 | 2013 | 115 | 0.100 |
Why?
|
| Thalidomide | 1 | 2012 | 24 | 0.100 |
Why?
|
| Nephrogenic Fibrosing Dermopathy | 1 | 2012 | 7 | 0.100 |
Why?
|
| Off-Label Use | 1 | 2012 | 17 | 0.100 |
Why?
|
| Recombinant Proteins | 4 | 2017 | 742 | 0.100 |
Why?
|
| Biostatistics | 1 | 2012 | 43 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 64 | 0.100 |
Why?
|
| United States | 7 | 2019 | 7367 | 0.100 |
Why?
|
| Taxoids | 1 | 2011 | 41 | 0.100 |
Why?
|
| Prostatic Neoplasms | 1 | 2017 | 778 | 0.090 |
Why?
|
| Premedication | 1 | 2011 | 49 | 0.090 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2011 | 42 | 0.090 |
Why?
|
| Darbepoetin alfa | 3 | 2017 | 13 | 0.090 |
Why?
|
| Paclitaxel | 1 | 2011 | 140 | 0.090 |
Why?
|
| Incidence | 3 | 2019 | 1603 | 0.090 |
Why?
|
| Comprehension | 1 | 2009 | 71 | 0.080 |
Why?
|
| Chlorhexidine | 1 | 2008 | 12 | 0.080 |
Why?
|
| Ulcer | 1 | 2008 | 27 | 0.080 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2008 | 40 | 0.080 |
Why?
|
| Dermatologic Agents | 1 | 2008 | 32 | 0.080 |
Why?
|
| Methotrexate | 1 | 2008 | 91 | 0.080 |
Why?
|
| Psoriasis | 1 | 2008 | 46 | 0.080 |
Why?
|
| Adenine | 2 | 2019 | 46 | 0.080 |
Why?
|
| Piperidines | 2 | 2019 | 123 | 0.070 |
Why?
|
| Female | 11 | 2019 | 38074 | 0.070 |
Why?
|
| Internet | 1 | 2009 | 390 | 0.070 |
Why?
|
| Aphasia | 1 | 2008 | 119 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 767 | 0.070 |
Why?
|
| Drug Approval | 2 | 2019 | 50 | 0.070 |
Why?
|
| Acute Kidney Injury | 1 | 2008 | 232 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2017 | 7029 | 0.060 |
Why?
|
| Middle Aged | 7 | 2017 | 21147 | 0.060 |
Why?
|
| Anticoagulants | 2 | 2019 | 356 | 0.060 |
Why?
|
| Male | 8 | 2019 | 37321 | 0.050 |
Why?
|
| Polyethylene Glycols | 2 | 2013 | 149 | 0.050 |
Why?
|
| Ethanol | 1 | 2008 | 893 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2009 | 2800 | 0.050 |
Why?
|
| Aged | 4 | 2019 | 14862 | 0.050 |
Why?
|
| Alcoholism | 1 | 2008 | 1109 | 0.040 |
Why?
|
| Coinfection | 1 | 2019 | 30 | 0.040 |
Why?
|
| Risk Factors | 2 | 2019 | 5731 | 0.040 |
Why?
|
| Hematologic Agents | 1 | 2019 | 11 | 0.040 |
Why?
|
| Virus Replication | 1 | 2019 | 104 | 0.040 |
Why?
|
| Japan | 1 | 2019 | 68 | 0.040 |
Why?
|
| Tungsten | 1 | 2018 | 3 | 0.040 |
Why?
|
| Preservatives, Pharmaceutical | 1 | 2018 | 4 | 0.040 |
Why?
|
| Excipients | 1 | 2018 | 8 | 0.040 |
Why?
|
| Syringes | 1 | 2018 | 15 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2018 | 87 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 196 | 0.040 |
Why?
|
| Drug Hypersensitivity | 1 | 2018 | 35 | 0.040 |
Why?
|
| Veterans Health | 1 | 2019 | 62 | 0.040 |
Why?
|
| Hepatitis C, Chronic | 1 | 2019 | 86 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2018 | 215 | 0.040 |
Why?
|
| Canada | 1 | 2019 | 267 | 0.040 |
Why?
|
| South Carolina | 2 | 2017 | 2752 | 0.040 |
Why?
|
| Erythropoiesis | 1 | 2017 | 24 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2019 | 307 | 0.040 |
Why?
|
| Adult | 4 | 2017 | 21403 | 0.040 |
Why?
|
| Therapeutic Equivalency | 1 | 2016 | 21 | 0.040 |
Why?
|
| Drug and Narcotic Control | 1 | 2016 | 15 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2019 | 373 | 0.030 |
Why?
|
| SEER Program | 1 | 2017 | 153 | 0.030 |
Why?
|
| Medicare | 1 | 2017 | 319 | 0.030 |
Why?
|
| Lymphoma, Primary Cutaneous Anaplastic Large Cell | 1 | 2014 | 2 | 0.030 |
Why?
|
| Hodgkin Disease | 1 | 2014 | 27 | 0.030 |
Why?
|
| Mycosis Fungoides | 1 | 2014 | 16 | 0.030 |
Why?
|
| Drug Incompatibility | 1 | 2013 | 7 | 0.030 |
Why?
|
| Drug Stability | 1 | 2013 | 71 | 0.030 |
Why?
|
| Drug Compounding | 1 | 2013 | 34 | 0.030 |
Why?
|
| Young Adult | 2 | 2017 | 5717 | 0.030 |
Why?
|
| Mass Screening | 1 | 2019 | 843 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 1420 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2013 | 120 | 0.030 |
Why?
|
| Connecticut | 1 | 2012 | 13 | 0.030 |
Why?
|
| Lawyers | 1 | 2012 | 4 | 0.030 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2013 | 47 | 0.030 |
Why?
|
| Lobbying | 1 | 2012 | 11 | 0.030 |
Why?
|
| Hematology | 1 | 2012 | 10 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2013 | 94 | 0.030 |
Why?
|
| Public Opinion | 1 | 2012 | 32 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 561 | 0.020 |
Why?
|
| Gadolinium | 1 | 2012 | 88 | 0.020 |
Why?
|
| Venous Thromboembolism | 1 | 2012 | 117 | 0.020 |
Why?
|
| Data Collection | 1 | 2012 | 420 | 0.020 |
Why?
|
| Aspirin | 1 | 2012 | 295 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2012 | 254 | 0.020 |
Why?
|
| Survival Rate | 1 | 2012 | 1056 | 0.020 |
Why?
|
| Hand Disinfection | 1 | 2008 | 9 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 1173 | 0.020 |
Why?
|
| Eating | 1 | 2008 | 119 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 772 | 0.020 |
Why?
|
| Research Design | 1 | 2012 | 729 | 0.020 |
Why?
|
| Drug Overdose | 1 | 2008 | 67 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 4848 | 0.020 |
Why?
|
| Prevalence | 1 | 2012 | 1619 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 1536 | 0.020 |
Why?
|
| Inpatients | 1 | 2008 | 208 | 0.020 |
Why?
|
| Prognosis | 1 | 2012 | 2093 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2012 | 2007 | 0.020 |
Why?
|
| Time Factors | 1 | 2013 | 4655 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2011 | 2358 | 0.020 |
Why?
|
| Quality of Life | 1 | 2013 | 1515 | 0.020 |
Why?
|
| Adolescent | 1 | 2017 | 8912 | 0.010 |
Why?
|